STERIS plc (STE) Stock Analysis 2026

HealthcareMedical Devices
$222.66
as of 2026-10-16
-15.0% (52-week)50D MA $223.52  |  200D MA $233.55

BriMind AI Score

Proprietary
51
Neutral
Price CAGR
12.9%
1Y Return
-9.1%
Analyst Upside
+22.7%
Rev Growth
7.3%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$242.42+8.9% potential
Bear Case
$194.59
Bull Case
$298.77
Model Confidence90%

An even blend of the BriMind AI model's DCF and momentum target ($222.70) and Wall Street's consensus target ($262.14).

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

STE Revenue & Profitability Breakdown

This chart shows how STE's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$6.04B
Cost of Revenue
-$3.36B
Gross Profit
$2.68B44.4% margin
Operating Expenses
-$1.53B
Operating Income
$1.16B19.2% margin
Tax & Other
-$351.4M
Net Income
$805.0M13.3% margin
Gross Margin
44.4%
Operating Margin
19.2%
Net Margin
13.3%
EBITDA Margin
26.8%

Key Financial Metrics

STERIS plc trades at a trailing P/E of 28.58x, generates $798.9M in free cash flow, runs a debt/equity ratio of 28.31, and converts shareholder equity into profit at a 11.4% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$22.79B
Enterprise Value
$26.02B
P/E (Trailing)
28.58
P/E (Forward)
19.09
PEG Ratio
1.97
EV / EBITDA
17.77
Price / Sales
4.39
Price / Book
3.63
Revenue
$6.04B
Revenue Growth
7.3%
Earnings Growth
14.0%
EBITDA
$1.46B
Gross Margin
44.4%
Operating Margin
19.2%
Net Margin
13.3%
Return on Equity
11.4%
Return on Assets
6.8%
Free Cash Flow
$798.9M
Total Cash
$171.7M
Total Debt
$2.20B
Debt / Equity
28.31
Current Ratio
1.91
Quick Ratio
1.17
Beta
0.91
Dividend Yield
1.1%
Payout Ratio
30.8%
Insider Ownership
0.3%
Inst. Ownership
100.5%
Short % Float
2.4%
Book Value / Share
$73.92

Wall Street Analyst Consensus

9 analysts covering STERIS plc currently lean toward a Buy rating, with a mean 12-month price target of $263.13 (+18.2% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingBuy(9 analysts)
SellStrong Buy
Low Target$231.003.7%
Mean Target$263.13+18.2% upside
High Target$280.00+25.8%

Intrinsic Value Estimates for STE

We use 1 valuation model to estimate STE's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

DCF Model (10yr)
$170.54
-23.4% vs current
Discounts 10 years of projected free cash flow back to today's dollars (5% growth, 10% discount rate). Best for companies generating consistent cash.
Fair Value Range
$170.54 – $170.54
Average Estimate
$170.54
Potential Downside
-23.4%

Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

Technical Price Signals

STE is currently in a death cross pattern, trading below its 50-day average of $223.52 and below its 200-day average of $233.55. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$222.66
50-Day MA
$223.52
▼ Price below
200-Day MA
$233.55
▼ Price below
Death Cross Pattern
Price below both MAs — bearish signal

Compare STE with Peers

STE vs DHRSTERIS vs Danaher — Sterile Processing vs Life Science
STE vs MMMSTERIS vs 3M Medical — Sterile Processing vs Industrial

More Healthcare Stock Analysis

In-depth reports on companies operating alongside STE — business models, bull and bear cases, and the metrics that matter.

BSXBoston Scientific CorporationMedical DevicesEWEdwards Lifesciences CorporationMedical DevicesDXCMDexCom, Inc.Medical DevicesGEHCGE HealthCare Technologies Inc.Medical DevicesMDTMedtronic plcMedical DevicesZBHZimmer Biomet Holdings, Inc.Medical DevicesSYKStryker CorporationMedical DevicesVEEVVeeva Systems Inc.Health Information Services

Unlock the Full STE Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis